About This Program
This program aims to develop anti-CD70 therapeutic fusion protein for immuno-oncology.
Chimeric fusion proteins, with their ability to extend plasma half-life and prolong therapeutic activity, offer exciting benefits over antibody-based therapeutics. Many companies are actively investigating fusion protein therapeutics as a promising alternative to antibodies.
CD70, a member of the tumor necrosis factor (TNF) family of ligands, functions to activate the co-stimulatory receptor CD27 to enhance T-cell-modulated immune responses. CD70-FP (fusion protein) binds to its co-stimulatory surface receptor CD27 that is expressed on T lymphocytes. The binding activity in term activates T lymphocytes, causing these cells to proliferate and suppress the activity of regulatory T cells (Treg). This process promotes the cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells, highlighting a clear rationale for CD70-FP-based cancer immunotherapy.
CD70
CD70 is the membrane-bound ligand of the CD27 receptor, which belongs to the tumor necrosis factor receptor superfamily. CD70 is transiently expressed on activated B and T cells, and mature dendritic cells. It interacts with its receptor CD27 that is more widely expressed on various subsets of B and T cells, and on a subset of natural killer (NK) cells. CD70-mediated effects are generally based on activation of CD27-associated signaling pathways. Here, we show the MOA of CD70/CD27-based agonists for cancer therapy. (see fig1).
-
CD70 is highly expressed on malignant cells and thus a bona-fide target for antiCD70 antibody-based therapy.
-
CD70 scFv-targeted TRAIL/FasL-based fusion proteins could be used to selectively deliver and locally activate proapoptotic signaling.
-
Utilizing anti-CD27 scFv as a bispecific antibody to bind a tumor-specific targeting antibody fragment may ensure selective modulation and/or inhibition of CD27 signaling in the tumor micro-environment.
Fig.1 CD70/CD27-based agonists for cancer therapy.1
CD70 Fusion Protein in Cancer Studies
Here are some published data about CD70 fusion protein work as a potential combination target for cancer immunotherapy.
-
PD1-CD70 fusion protein (DSP106) Inhibits tumor growth in syngeneic colon carcinoma.
Indication
The expression of CD70 has been confirmed on many hematological malignancies and carcinomas. Our program primarily focuses on the development of therapeutic antibodies against the high-risk NHL.
Clinical Trials under Progress
Currently, to the best of our knowledge, there are NO ongoing clinical trials of the CD70 fusion protein. Our program will be a pioneer in the development of CD70 fusion proteins.
Program Plan
Creative Biolabs has established the novel chimeric fusion protein platform for Agonist Redirected Checkpoint (ARC) program development. We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years prior to entering the IND stage.
Currently, based on our state-of-art chimeric fusion protein platform, Creative Biolabs is planning to develop the following programs (including but not limited to):
-
Fc-CD70 Fusion Protein Program
-
(checkpoint)-CD70 Fusion Protein Program
-
scfv: CD70-(TNF family member) Fusion Program
Fig.2 The timeline of Next-IOᵀᴹ programs.
Cooperation
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-CD70 therapeutic fusion protein program together. Our scientists are dedicated to bringing together years of valuable experience to our partner and achieve a meaningful partnership. By doing so, we wish to help both parties to proceed with IND and many stages of clinical trials beyond.
If you are interested, please feel free to contact us so that we can discuss the program and other possible opportunities for cooperation. Look forward to working with you in the near future.
Download our brochure